Dr. Xiaodong (Eric) Wu has over 20 years of experience in the pharmaceutical industry, specializing in business development, research and development, and investment. Before joining Biomissile, he served as the Vice President of Business Development and Operations at Kanova Biopharma, where he was responsible for business development and external partnerships. Prior to that, he was the Director of Business Development at Reistone Biopharma, leading the in-licensing and collaboration efforts for multiple autoimmune projects. Dr. Wu also served as the International Business Development Manager at Qilu Pharmaceuticals, where he facilitated partnerships with renowned international research institutes and played a key role in advancing several innovative projects. During his time at Johnson & Johnson in the U.S., Dr. Wu worked in the pharmacogenomics department, overseeing the statistical design of pharmacogenomic studies and contributing to FDA submissions. He was also an Assistant Professor at Loyola Medical School in Chicago, where he published more than 20 papers in prestigious international journals.

Dr. Wu holds a Ph.D. from Texas A&M University and an MBA from New York University, and he completed postdoctoral research at the University of Chicago.